GLP-1 Biology
Physiology research | Gut-Brain • Glucose • Gastric Motility
Common names: GLP-1 · glucagon-like peptide-1 · incretin · gut-brain signaling · gastric emptying
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
GLP-1 is a hormone your body already uses to help manage blood sugar, stomach emptying and appetite. Drugs that target GLP-1 build on that biology, but they create a much longer and stronger signal than the natural hormone. So GLP-1 biology and a GLP-1 drug are related, but they are not the same thing.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying GLP-1 Biology across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Foundational / Established
- Selected source context
- Human · Mixed · Research Review
At a Glance
Research snapshot.
- 01Research Base
Mechanistic and human physiology - 02Research Stage
Foundational / Established - 03Key Distinction
Endogenous and pharmacologic exposure differ - 04Pathway Complexity
Not one mechanism
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
GLP-1 participates in glucose-dependent insulin secretion and glucagon regulation.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- endogenous GLP-1 physiology
Explore the evidence
human direct
Human solid gastric-emptying study.
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
4V Take
GLP-1 can slow gastric emptying and thereby influence postprandial glucose handling.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- gastric emptying
Explore the evidence
human direct
Human solid gastric-emptying study.
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
Related pathways
4V Take
Gastric-emptying effects can show tachyphylaxis and differ among short- and long-acting pharmacologic agonists.
- Evidence bucket
- human clinical
- Research stage
- established
- Route / format
- short- and long-acting pharmacologic agonists
Explore the evidence
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human direct
Human solid gastric-emptying study.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
4V Take
GLP-1 signaling influences appetite/satiation through central and peripheral gut-brain pathways; precise contributions remain incompletely resolved.
- Evidence bucket
- mixed
- Research stage
- established
- Route / format
- central and peripheral gut-brain pathways
Explore the evidence
human direct
Human solid gastric-emptying study.
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
4V Take
Endogenous GLP-1 and pharmacologic GLP-1 receptor agonists should not be treated as biologically identical exposures.
- Evidence bucket
- mixed
- Research stage
- established
- Route / format
- endogenous hormone and pharmacologic agonists
Explore the evidence
human direct
Human solid gastric-emptying study.
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
Related pathways
4V Take
GLP-1 biology should not be used as a blanket explanation for the full effects of dual- or triple-agonist drugs.
- Evidence bucket
- mixed
- Research stage
- established
- Route / format
- dual- and triple-agonist pharmacology
Explore the evidence
human direct
Human solid gastric-emptying study.
human direct
Rapid gastric-emptying tachyphylaxis RCT.
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
Human solid gastric-emptying study.
1999 · PMID: 10484511 · peer reviewed
human direct
Rapid gastric-emptying tachyphylaxis RCT.
2011 · PMID: 21430088 · peer reviewed
human synthesis
GLP-1 physiology informs obesity pharmacotherapy.
2021 · PMID: 34626851 · peer reviewed
human synthesis
Revisiting GLP-1 action complexity.
2020 · PMID: 33320179 · peer reviewed
human synthesis
Human GLP-1 physiology review.
2005 · PMID: 15780430 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Related Research
Continue with context.
Connections are limited to approved topic context. Each linked topic keeps its own evidence boundaries and Research Stage.
Semaglutide
Foundational biologyGLP-1 Biology provides native-pathway context for semaglutide without treating natural hormone signaling and prescription-drug exposure as the same evidence question.
Research Stage: Established
Native physiology and therapeutic evidence remain separate.
Retatrutide
Foundational biologyGLP-1 Biology provides pathway context for one receptor included in retatrutide’s investigated profile.
Research Stage: Phase 3
Pathway biology and therapeutic evidence remain separate.
Tirzepatide
Foundational biologyGLP-1 Biology provides pathway context for one receptor included in tirzepatide’s approved dual-agonist profile.
Research Stage: Established for approved indications
Pathway biology and therapeutic evidence remain separate.
GIP Biology
Related physiologyThese topics describe distinct incretin pathways and keep native physiology separate from drug effects.
Research Stage: Foundational / Developing
Read the Research Stage on each topic independently.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.